Read More

IceCure Medical Reports Data From Its Kidney Cancer Clinical Study Presented At Interventional Radiology Conference Dsud Minimally Invasive Approach Results In Shorter Hospitalization And Minor Impact On Renal Function

ICESECRET interim results, as previously announced, demonstrated ProSense® to be safe and effective in treating kidney tumors with 89.5% recurrence-free rateMore data is expected in the fourth quarter of 2024,

ICCM